Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

April 5, 2023

Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
March 2, 2023

Immunic to Participate in Investor and Scientific Conferences in March
February 23, 2023

Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update
February 22, 2023

Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
February 16, 2023

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
February 9, 2023

Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
January 25, 2023

Immunic to Participate in Scientific and Investor Conferences in February
November 17, 2022

Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential
November 10, 2022

Immunic to Participate in Investor and Scientific Conferences in November and December
November 3, 2022

Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 27, 2022

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
October 20, 2022

Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate
October 10, 2022

Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
October 4, 2022

Immunic to Participate in Scientific and Industry Conferences in October
September 20, 2022

Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects
September 1, 2022

Immunic, Inc. to Participate in Investor Conferences in September
August 16, 2022

Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium
August 4, 2022

Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 2, 2022

Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
July 28, 2022

Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
July 6, 2022

Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén
June 28, 2022

Immunic to Participate in Industry and Scientific Conferences in July
June 15, 2022

Immunic Announces Publication of Data From Its Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in Peer Reviewed Journal, Annals of Clinical and Translational Neurology
June 8, 2022

Immunic, Inc. to Participate in Scientific, Industry and Investor Conferences in June
June 2, 2022

Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update

Show per page